Clinical Research Directory

A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice

Sponsor: Takeda

Summary

The main aim of this study is to check for side effects from treatment with niraparib. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with ovarian cancer will take capsules of niraparib (Zedula) once a day according to their clinic's standard practice. The study doctors will check for side effects from niraparib for 1 year after treatment starts.

Official title: Zedula Special Drug Use Observational Study "Ovarian Cancer"

Key Details

Conditions

Interventions

Locations (1)